Edition:
United States

Mylan NV (MYL.O)

MYL.O on Nasdaq

38.51USD
20 Oct 2017
Change (% chg)

$0.22 (+0.57%)
Prev Close
$38.29
Open
$38.43
Day's High
$38.63
Day's Low
$37.95
Volume
3,998,501
Avg. Vol
6,475,659
52-wk High
$45.87
52-wk Low
$29.39

Summary

Name Age Since Current Position

Robert Coury

2016 Chairman of the Board

Rajiv Malik

2016 President, Executive Director

Heather Bresch

2016 Chief Executive Officer, Executive Director

Kenneth Parks

53 2016 Chief Financial Officer

Dennis Zeleny

2017 Chief Human Resource Officer

Daniel Gallagher

2017 Chief Legal Officer

Anthony Mauro

2016 Chief Commercial Officer

Sjoerd Vollebregt

2017 Independent Director

Wendy Cameron

2016 Non-Executive Independent Director

Robert Cindrich

2016 Non-Executive Independent Director

JoEllen Dillon

2016 Non-Executive Independent Director

Neil Dimick

68 2016 Non-Executive Independent Director

Melina Higgins

49 2016 Non-Executive Independent Director

Mark Parrish

2016 Non-Executive Independent Director

Randall Vanderveen

2016 Non-Executive Independent Director

Biographies

Name Description

Robert Coury

Mr. Robert J. Coury is Chairman of the Board of Mylan Inc. He has been the Executive Chairman of Mylan and the Mylan Board since January 2012. Mr. Coury was first elected to the Mylan Board in February 2002, having served since 1995 as a strategic advisor to the Company. He became the Mylan Board’s Vice Chairman shortly after his election and served as CEO of the Company from September 2002 until January 2012. Since 2007, Mr. Coury has led the Company through a series of transactions totaling approximately $15 billion, which transformed the Company into a global powerhouse within the highly competitive pharmaceutical industry. In 2007, Mylan purchased India-based Matrix Laboratories, a major producer of active pharmaceutical ingredients, and the generics business of Europe-based Merck KGaA. Subsequent acquisitions under Mr. Coury’s leadership further expanded the Company into new therapeutic categories and greatly enhanced its geographic and commercial footprint. For instance, in 2010, Mylan acquired Bioniche Pharma, an injectables business in Ireland, and in 2012, Mylan acquired India-based Agila Specialties, a global injectables company. Most recently, the Company completed its acquisition of Abbott Laboratories’ non-U.S. developed markets specialty and branded generics business.

Rajiv Malik

Mr. Rajiv Malik is President, Executive Director of Mylan Inc. He has served as Mylan’s President since January 1, 2012. Previously, Mr. Malik held various senior roles at Mylan, including Executive Vice President and Chief Operating Officer from July 2009 to December 2012, and Head of Global Technical Operations from January 2007 to July 2009. In addition to his oversight of day-to-day operations of the Company as President, Mr. Malik has been instrumental in identifying, evaluating, and executing on significant business development opportunities, expanding and optimizing Mylan’s product portfolio, and leveraging Mylan’s global research and development capabilities, among other important contributions. Previously, he served as Chief Executive Officer of Matrix Laboratories Limited (n/k/a Mylan Laboratories Limited) from July 2005 to June 2008. Prior to joining Matrix, he served as Head of Global Development and Registrations for Sandoz GmbH from September 2003 to July 2005. Prior to joining Sandoz, Mr. Malik was Head of Global Regulatory Affairs and Head of Pharma Research for Ranbaxy from October 1999 to September 2003.

Heather Bresch

Ms. Heather M. Bresch is Chief Executive Officer, Executive Director of Mylan Inc. She has served as Mylan’s Chief Executive Officer (“CEO”) since January 1, 2012. Throughout her 24-year career with Mylan, Ms. Bresch has held roles of increasing responsibility in more than 15 functional areas. Prior to becoming CEO, Ms. Bresch was Mylan’s President commencing in July 2009 and was responsible for the day-to-day operations of the Company. Before that, she served as Mylan’s Chief Operating Officer and Chief Integration Officer from October 2007 to July 2009, leading the integration of two transformational international acquisitions – Matrix Laboratories Limited (n/k/a Mylan Laboratories Limited) and Merck KGaA’s generics and specialty pharmaceuticals businesses. Under Ms. Bresch’s leadership, Mylan has continued to expand its portfolio and geographic reach, acquiring Abbott Laboratories’ non-U.S. developed markets specialty and branded generics business, the female healthcare business of Famy Care Ltd., and India-based Agila Specialties, a global leader in injectable products and an innovative respiratory technology platform; partnering on portfolios of biologic and insulin products; entering new commercial markets such as India and Brazil; and expanding its leadership in the treatment of HIV/AIDS through the distribution of novel testing devices. During her career, Ms. Bresch has championed initiatives aimed at improving product quality and removing barriers to patient access to medicine.

Kenneth Parks

Mr. Kenneth (Ken) Scott Parks has been appointed as Chief Financial Officer of Mylan N.V., effective 6 June 2016. Mr. Parks will hold the office of Chief Financial Officer until his successor is appointed, or until his death, resignation, or removal. Mr. Parks currently serves as chief financial officer for WESCO International (“WESCO”), a leading provider of electrical, industrial, and communication products. He has held that post since June 2012, and in that position, has led all aspects of the finance function at WESCO. From June 2012 to December 2013 he also served as a vice president at WESCO, and since January 2014, he has also served as senior vice president. Prior to joining WESCO, Mr. Parks spent the majority of his career at United Technologies Corporation.

Dennis Zeleny

Mr. Dennis Zeleny is Chief Human Resource Officer of the Company. In the corporate realm, Zeleny served as senior vice president and chief human resources officer at Sunoco Inc. and Sunoco Logistics Partners, where he was responsible for all Human Resources, Communications, Public Affairs, Aviation, Medical and other administrative areas for these two publicly traded companies. During his tenure, he played an integral role in guiding Sunoco as it worked to restructure the company's business portfolio, while revitalizing its performance culture. Previously, Zeleny was executive vice president, Administration and Services at Caremark Rx, where he led Human Resources, Communications, Public Relations and other internal administrative functions prior to its sale to CVS. Zeleny earned a Bachelor of Science from Cornell University and a master's degree from Columbia University's Graduate School of Business.

Daniel Gallagher

Mr. Daniel M. Gallagher is Chief Legal Officer of Mylan N.V. Gallagher joins Mylan from Patomak Global Partners, a consulting firm providing strategic advice, compliance consulting, and litigation and regulatory enforcement services, where he was president. FromNov. 2011toOct. 2015, Gallagher served as a commissioner of the U.S. Securities and Exchange Commission (SEC). During his tenure at the SEC, he focused on initiatives aimed at strengthening the U.S. capital markets and encouraging capital formation. As commissioner, he called for reform on various corporate governance issues, advocated for conducting a comprehensive holistic review of equity market structure issues, and encouraged building the Commission's fixed income market expertise. Before being appointed commissioner, Gallagher served on the staff of the SEC in several capacities, including as counsel to both SEC CommissionerPaul Atkinsand ChairmanChristopher Cox, working on matters involving the Division of Enforcement and the Division of Trading and Markets. Gallagher served as deputy director and co-acting director of the Division of Trading and Markets from 2008 to 2010, where he was on the front lines of the agency's response to the financial crisis, including representing the Commission in the Lehman Brothers liquidation. Gallagher received his B.A. in English from Georgetown University and his J.D., magna cum laude, from the Catholic University of America, where he was a member of the Law Review. Gallagher serves as non-executive director of both the Irish Stock Exchange and Symbiont.io, and is on the advisory board of the Drexel LeBow Center for Corporate Governance.

Anthony Mauro

Mr. Anthony Mauro is Chief Commercial Officer of Mylan N.V. since January 4, 2016. Prior to that date, Mr. Mauro served as President, North America of Mylan since January 1, 2012. He served as President of Mylan Pharmaceuticals Inc. from 2009 through February 2013. In his 20 years at Mylan, Mr. Mauro has held roles of increasing responsibility, including Chief Operating Officer for Mylan Pharmaceuticals ULC in Canada and Vice President of Strategic Development, North America, and Vice President of Sales, North America for Mylan.

Sjoerd Vollebregt

Mr. Sjoerd S. Vollebregt has served as Independent Director of the Company., since June 22, 2017. He currently serves as the chairman of the Supervisory Board of Heijmans N.V., a Euronext Amsterdam listed company operating in property development, residential building, non-residential building, roads and civil engineering, and as chairman of the Advisory Board of Airbus Defence and Space Netherlands B.V., a subsidiary of Airbus SE, a Euronext Paris listed company, that develops solar arrays, satellite instruments and structures for launchers. Previously, Mr. Vollebregt served as chairman of the Executive Board of Stork B.V., an Amsterdam Stock Exchange-listed industrial group, and as chief executive officer of Fokker Technologies Group B.V., an aerospace company and a Stork B.V. subsidiary. Mr. Vollebregt also has previously served as a member of the Supervisory Board of TNT Express N.V., an international courier delivery services company, and has held various other senior positions at Exel plc, Ocean plc, Intexo Holding andRoyal Van Ommeren.

Wendy Cameron

Ms. Wendy Cameron is Non-Executive Independent Director of Mylan Inc. She has served as Co-Owner and Director of Cam Land LLC, a harness racing business in Washington, Pennsylvania, since January 2003. From 1981 to 1998, she was Vice President, Divisional Sales & Governmental Affairs, Cameron Coca-Cola Bottling Company, Inc. Ms. Cameron served as Chairman of the Washington Hospital Board of Trustees and of the Washington Hospital Executive Committee until she stepped down in 2012. She was a member of the hospital’s Board of Trustees from 1997 through 2012 and a member of the Washington Hospital Foundation Board from 1993 through 2012. In addition to being a business owner and having held an executive position with one of the nation’s largest bottlers for nearly 20 years, Ms. Cameron has invaluable experience and knowledge regarding the business, platforms, strategies, challenges, opportunities, and management of the Company, among other matters. Ms. Cameron’s qualifications to serve on the Mylan Board include, among others, this experience, as well as her independence, business experience, leadership, and judgment.

Robert Cindrich

Hon. Robert J. Cindrich is Non-Executive Independent Director of Mylan Inc. He has been serving as the President of Cindrich Consulting, LLC, a business and healthcare consulting company that advises clients on corporate governance, compliance, and business strategies, and from October 1, 2013 through January 31, 2014 he served as Interim General Counsel for United States Steel Corporation (NYSE: X). He joined Schnader Harrison Segal & Lewis (“Schnader”), a law firm, as legal counsel in April 2013 and took a temporary leave of absence on October 1, 2013 to join United States Steel as Interim General Counsel, returning to Schnader after his time at United States Steel. In May 2012, he joined the Board of Directors of Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX), which provides healthcare information technology solutions, where he served until April 2015. From 2011 through 2012, he served as a senior advisor to the Office of the President of the University of Pittsburgh Medical Center (“UPMC”), an integrated global health enterprise. From 2004 through 2010, he was a Senior Vice President and the Chief Legal Officer of UPMC. From 1994 through January 2004, he served as a judge on the United States District Court for the Western District of Pennsylvania. Prior to that appointment, he was active as an attorney in both government and private practice, including positions as the U.S. Attorney for the Western District of Pennsylvania and as the Allegheny County Assistant Public Defender and Assistant District Attorney.

JoEllen Dillon

Ms. JoEllen Lyons Dillon is Non-Executive Independent Director of Mylan N.V. She has served as Chief Legal Officer and Corporate Secretary of The ExOne Company (NASDAQ: XONE), a global provider of three-dimensional printing machines, since March 2013, and as Executive Vice President since December 2014. Previously, she was a legal consultant on ExOne’s initial public offering. Prior to that experience, Ms. Dillon was a partner with Reed Smith LLP, a law firm, from 2002 until 2011. She had previously been at the law firm Buchanan Ingersoll & Rooney PC from 1988 until 2002, where she became a partner in 1997. Ms. Dillon is the former Chair, and currently serves as the Audit Committee Chair of, the Allegheny District chapter of the National Multiple Sclerosis Society.

Neil Dimick

Mr. Neil F. Dimick, CPA, is Non-Executive Independent Director of Mylan NV. Currently retired, Mr. Dimick previously served as Executive Vice President and Chief Financial Officer of AmerisourceBergen Corporation (NYSE: ABC), a wholesale distributor of pharmaceuticals, from 2001 to 2002. From 1992 to 2001, he was Senior Executive Vice President and Chief Financial Officer of Bergen Brunswig Corporation, a wholesale drug distributor. Prior to that experience, Mr. Dimick served as a partner with Deloitte for eight years. Mr. Dimick also serves on the Boards of Directors of WebMD Health Corp. (NASDAQ: WBMD), Alliance HealthCare Services, Inc. (NASDAQ: AIQ), and Resources Connection, Inc. (NASDAQ: RECN). Mr. Dimick also served on the Boards of Directors of Thoratec Corporation from 2003 to October 2015, at which time it was purchased by St. Jude Medical, Inc., and HLTH Corporation from 2002 to 2009, at which time it was merged into WebMD Health Corp. Mr. Dimick has invaluable experience and knowledge regarding the business, platforms, strategies, challenges, opportunities, and management of the Company, among other matters. Mr. Dimick’s qualifications to serve on the Mylan Board include, among others, this experience, as well as his independence, substantial industry experience, judgment, business and accounting background, and judgment.

Melina Higgins

Ms. Melina E. Higgins is Non-Executive Independent Director of Mylan NV. Currently retired, Ms. Higgins held senior roles of increasing responsibility at The Goldman Sachs Group, Inc. (NYSE: GS), including Partner and Managing Director, during her nearly 20-year career at the firm from 1989 to 1992 and 1994 to 2010. During her tenure at Goldman Sachs, Ms. Higgins served as a member of the Investment Committee of the Principal Investment Area, which oversaw and approved global private equity and private debt investments and was one of the largest alternative asset managers in the world. She also served as head of the Americas and as co-chairperson of the Investment Advisory Committee for the GS Mezzanine Partners funds, which managed over $30 billion of assets and were global leaders in their industry. Ms. Higgins also serves on the Women’s Leadership Board of Harvard University’s John F. Kennedy School of Government. In September 2013, Ms. Higgins joined the Board of Directors of Genworth Financial Inc. (NYSE: GNW), an insurance company. In January 2016, Ms. Higgins became non-executive Chairman of Antares Midco Inc., a private company that provides financing solutions for middle-market, private equity-backed transactions. Ms. Higgins’ qualifications to serve on the Mylan Board include, among others, her independence, broad experience in finance, and judgment.

Mark Parrish

Mr. Mark W. Parrish is Non-Executive Independent Director of Mylan Inc. He has served as Chairman and Chief Executive Officer of TridentUSA Health Services, a provider of mobile X-ray and laboratory services to the long-term care industry, since 2008. Since January 2013, Mr. Parrish has also served on the Board of Directors of Omnicell, Inc. (NASDAQ: OMCL), a company that specializes in healthcare technology. Mr. Parrish also serves on the Boards of Directors of Silvergate Pharmaceuticals, a private company that develops and commercializes pediatric medications, and GSMS, a private company that specializes in meeting unique labeling and sizing needs for its customers and pharmaceutical packaging, serialization, and distribution. From 2001 to 2007, Mr. Parrish held management roles of increasing responsibility with Cardinal Health Inc. (NYSE: CAH) and its affiliates, including Chief Executive Officer of Healthcare Supply Chain Services for Cardinal Health from 2006 to 2007. Mr. Parrish also serves as President of the International Federation of Pharmaceutical Wholesalers, an association of pharmaceutical wholesalers and pharmaceutical supply chain service companies, and senior adviser to Frazier Healthcare Ventures, a healthcare oriented growth equity firm.

Randall Vanderveen

Dr. Randall (Pete) L. Vanderveen is Non-Executive Independent Director of Mylan Inc. He is currently Professor of Pharmaceutical Policy and Economics, Senior Adviser to the Leonard D. Schaeffer Center of Health Policy and Economics, Director of the Margaret and John Biles Center for Leadership, and Senior Adviser to the Dean for Advancement at the School of Pharmacy, University of Southern California in Los Angeles, California. Dr. Vanderveen previously served as Dean, Professor and John Stauffer Decanal Chair of the USC School of Pharmacy from 2005 to 2015 where he was named “Outstanding Pharmacy Dean in the Nation” in 2013 by the American Pharmacist Association. From 1998 to 2005, he served as Dean and Professor of Pharmacy of the School of Pharmacy and the Graduate School of Pharmaceutical Sciences at Duquesne University, before which he was Assistant Dean at Oregon State University from 1988 to 1998. In addition, Dr. Vanderveen has invaluable experience and knowledge regarding the business, platforms, strategies, challenges, opportunities, and management of the Company, among other matters. Dr. Vanderveen’s qualifications to serve on the Mylan Board include, among others, this experience, as well as his independence, pharmaceutical and leadership experience, and judgment.

Basic Compensation